Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Research output: Contribution to journalLetter

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)e86-e90
JournalBritish Journal of Haematology
Volume189
Issue number3
DOIs
StatePublished - May 1 2020

Keywords

  • Hodgkin lymphoma
  • autologous stem cell transplantation
  • bendamustine
  • brentuximab vedotin
  • first salvage therapy

ASJC Scopus subject areas

  • Hematology

Cite this

LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O’Connor, O. A., Josephson, N., Wang, Y., & Advani, R. (2020). Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 189(3), e86-e90. https://doi.org/10.1111/bjh.16499